Evidence map›Paper›PMID 37346921›Full record

ArticleThe Pan African medical journal2023

Co-administration of rimonabant prevents glucose intolerance in Sprague-Dawley rats treated chronically with lopinavir/ritonavir and zidovudine: an experimental study design.

Brian Lishenga Makamu, Peter Waweru Mwangi, Frederick Okonji Bukachi

Open access · goldAbstract read
In one paragraph

Article in The Pan African medical journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Brian Lishenga MakamuDepartment of Medical Physiology, Egerton University, P.O Box 536, 20115 Egerton, Kenya.
Peter Waweru MwangiDepartment of Medical Physiology, University of Nairobi, P.O Box 30197, 00100 Nairobi, Kenya.
Frederick Okonji BukachiDepartment of Medical Physiology, University of Nairobi, P.O Box 30197, 00100 Nairobi, Kenya.
University of Nairobi · KEEgerton University · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: treatment of HIV infection with Protease Inhibitors (PIs) and Nucleoside Reverse Transcriptase Inhibitors (NRTIs) can lead to insulin resistance and changes in body fat distribution. Overactivity of the endogenous cannabinoid system produces similar disturbances in metabolic syndrome within the general population. However, Cannabinoid receptor type 1 antagonism, in both human and animal studies, reverses many of these biochemical and physical derangements observed in the metabolic syndrome. Methods: using an experimental study design, fifteen adult male Sprague-Dawley rats housed under standard conditions were randomized into three groups; Control, combined Anti-Retroviral Therapy (cART) only and cART + rimonabant. Drugs were administered daily by oral gavage for four weeks. After four weeks, insulin tolerance tests were conducted, the rats were euthanised and fat depots were excised and weighed. Experimental data were analysed using STATA 16.0 with the significance level set at p<0.05. The Shapiro-Wilk test determined normalcy. In cases of significance, post hoc analysis was performed by either the Dunn test or the Tukey HSD test. Results: Sprague Dawley rats treated with cART + rimonabant demonstrated better insulin sensitivity (p = 0.0239) and lower body weight (p = 0.044) than rats treated with cART alone. They had leaner body composition with 58% less adiposity than cART-only rats. Conclusion: the study results suggest a role for the endogenous cannabinoid system in cART induced metabolic derangements and physical changes. Future studies can directly assay ECS activity in cART associated metabolic syndrome.

Indexed as

Anti-HIV AgentsCannabinoidsGlucose IntoleranceHIV InfectionsMetabolic SyndromeAdultAnimalsHumansLopinavirMaleRatsRats, Sprague-DawleyRimonabantRitonavirZidovudineAnti-HIV AgentsCannabinoidsLopinavirRimonabantRitonavirZidovudineAntiretroviral therapyendogenous cannabinoidsHIVhyperglycemiametabolic syndromenucleoside reverse transcriptase inhibitorsprotease inhibitorsrimonabant

Identifiers

PMID37346921
PMCPMC10280694
OpenAlexW4372061224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.